Search Results - "Santos, V Sacristan"

Molecular characterization of metastatic urothelial carcinoma (mUC) in prior or current smokers (PCS) vs non-smokers (NS) by Sacristan Santos, V., Esther, J., Maughan, B.L., Wesolowski, S., Lin, E., Hahn, A., Sirohi, D., Rathi, N., Swami, U., Nussenzveig, R., Agarwal, N.

Get full text

943PMolecular characterization of metastatic urothelial carcinoma (mUC) in prior or current smokers (PCS) vs non-smokers (NS) by Sacristan Santos, V, Esther, J, Maughan, B L, Wesolowski, S, Lin, E, Hahn, A, Sirohi, D, Rathi, N, Swami, U, Nussenzveig, R, Agarwal, N

“…Abstract Background Even though smoking is one of the most recognized risk factors, NS also develop mUC. Identifying molecular drivers of disease progression…”
Get full text

943P - Molecular characterization of metastatic urothelial carcinoma (mUC) in prior or current smokers (PCS) vs non-smokers (NS) by Sacristan Santos, V., Esther, J., Maughan, B.L., Wesolowski, S., Lin, E., Hahn, A., Sirohi, D., Rathi, N., Swami, U., Nussenzveig, R., Agarwal, N.

“…Even though smoking is one of the most recognized risk factors, NS also develop mUC. Identifying molecular drivers of disease progression in NS have the…”
Get full text

845PD - CDK12-altered prostate cancer: Clinical features and therapeutic outcomes to standard systemic therapies, PARP inhibitors, and PD1 inhibitors by Antonarakis, E.S., Velho, P Isaacsson, Agarwal, N., Santos, V Sacristan, Maughan, B.L., Pili, R., Adra, N., Sternberg, C.N., Vlachostergios, P.J., Tagawa, S.T., Bryce, A.H., McNatty, A.L., Reichert, Z.R., Dreicer, R., Sartor, O., Lotan, T.L., Hussain, M.

“…Although once considered a homologous recombination DNA repair gene, CDK12 is now thought to have a distinct role in maintaining genomic stability. In prostate…”
Get full text

CDK12-altered prostate cancer: Clinical features and therapeutic outcomes to standard systemic therapies, PARP inhibitors, and PD1 inhibitors by Antonarakis, E.S., Velho, P Isaacsson, Agarwal, N., Santos, V Sacristan, Maughan, B.L., Pili, R., Adra, N., Sternberg, C.N., Vlachostergios, P.J., Tagawa, S.T., Bryce, A.H., McNatty, A.L., Reichert, Z.R., Dreicer, R., Sartor, O., Lotan, T.L., Hussain, M.

Get full text

845PDCDK12-altered prostate cancer: Clinical features and therapeutic outcomes to standard systemic therapies, PARP inhibitors, and PD1 inhibitors by Antonarakis, E S, Velho, P Isaacsson, Agarwal, N, Santos, V Sacristan, Maughan, B L, Pili, R, Adra, N, Sternberg, C N, Vlachostergios, P J, Tagawa, S T, Bryce, A H, McNatty, A L, Reichert, Z R, Dreicer, R, Sartor, O, Lotan, T L, Hussain, M

“…Abstract Background Although once considered a homologous recombination DNA repair gene, CDK12 is now thought to have a distinct role in maintaining genomic…”
Get full text